Poisson Regression Modelling of the Effectiveness of the Meningococcal B Vaccine (MeNZB)

Poisson Regression Modelling of the Effectiveness …
31 Oct 2011
pdf
New Zealand experienced a prolonged epidemic of Meningococcal B disease starting in 1991 and peaking in 2001. In response, a strain-specific meningococcal B vaccine (MeNZB) was developed and offered through a national programme to all New Zealand children and teenagers under the age of 20 years from July 2004 to June 2006. MeNZB continued to be offered to babies until 1 June 2008. This report updates findings from earlier studies assessing the impact of the MeNZB vaccine, and forms the basis of published study (Arnold R, et al. 2011. Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand. Vaccine. 29(40): 7100–06).

Purpose

The main objective of this study is to apply a Poisson regression model of epidemic strain Meningococcal B disease rates in New Zealand in order to assess the impact of a new vaccine (MeNZB). The study design of a staged roll-out of the vaccine in different age groups and geographic regions allows for an estimation of the vaccine effect that is not confounded with the progression of the epidemic over time. The Poisson regression model considers the number of subjects at risk, as well as the time at risk, so that the disease rates are calculated as the average number of cases per person per unit of time. This method of estimating rates facilitates the incorporation of the rollout vaccination schedule. The analysis defines cases as individuals with the epidemic strain of meningococcal disease and estimates the effects of vaccination in different age and ethnic groups, while accounting for potential covariates of region-specific disease rates, deprivation, time, and seasonality.
Page last modified: 15 Mar 2018